1526 Treating Tyrosinemia Type 1: Experience from Kuwait

Sadeq, S; Nakhi, HA Bin; Naqeeb, Niran Al

doi:10.1136/archdischild-2012-302724.1526

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In general, the most diagnosed patients of inborn errors of metabolism (IEMs) including HT-1, were born from consanguineous married parents. As HT-1 is a rare inherited autosomal recessive disorder, it explains why it is more common in population with a high rate of consanguineous marriages, such as in United Arab Emirates, Oman, Kuwait, and Saudi Arabia, in which the rate of consanguineous marriages reaches up to approximately 60% [33,[77][78][79][80], and even the first reported case of HT-1 in Japan (1957) was a child from parents of consanguineous marriage [13,14]. Furthermore, in our study, the reported three family cases are also born from a consanguineous married parent.…”

Section: Discussionmentioning

confidence: 99%

Successive Drug Therapy for a Very Rare Autosomal Diseases

Al-Noaemi¹,

Daghriri²

2020

Drug Discovery and Development - New Advances

View full text Add to dashboard Cite

It is very rare to find reports concerning a drug therapy successively treating chromosomal abnormalities. In this paper, we are reporting a successive use of nitisinone in treating a fatal and very rare autosomal disease called hereditary tyrosinemia type-1 [HT-1]. HT-1 is affecting about one person in 100,000 to 120,000 births worldwide. It is due to a genetic defect in the enzyme fumarylacetoacetate hydroxylase (FAH), which is responsible for the final degradation of tyrosine. Accumulation of tyrosine metabolites is responsible for tissue damage such as liver, kidney, and neural tissues, finally causing the death of the newborn babies in their early months of life if not treated. Fumarylacetoacetate hydrolase gen has mapped on chromosome 15q23-15q25. Since 1992, the initiation of treating HT-1 with nitisinone (NTBC) has become the medical therapy of choice in combination with diet. NTBC therapy has shown a direct correlation between age of initiation and subsequent clinical course. We are reporting three brothers treated safely and successively with NTBC in combination with diet. All of them are in very good conditions. The elder brother is on NTBC since 27 years ago.

show abstract

Section: Discussionmentioning

confidence: 99%